Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Spinal Cord Med. 2021 Jan;44(1):89-95. doi: 10.1080/10790268.2019.1603490. Epub 2019 Apr 18.
To examine the hypothesis that what is the concomitant mechanism of action botulinum toxin type A (BoNTA) administration by intravesical electromotive into the bladder resulting in bladder function improvement. We also tried to confirm the possibility of retrograde trans-axonal transportation of toxin. Animal study. Ten male rabbits were divided into two groups. Group 1 (G1) ( = 5) (BoNTA/EMDA), and group 2 (G2) ( = 5) the control group. Animals in G1received 10 IU/Kg of intravesical BoNTA through a specific catheter for electromotive drug administration (BoNTA/EMDA). About 0.1-0.15 ml of toxin was diluted in 1 ml of distilled water. The maximum frequency of the device for drug solution delivery was set at 4 mA for 15 min. In G2 as the control group, the same procedure was performed to deliver normal saline to the bladder. Multiple biopsies were taken from bladder's contiguous structures one month postoperatively. The immunohistochemical (IHC) evaluation was performed with anti-clostridium botulinum toxoid type A mouse IgM monoclonal antibody. In specimens of G1, BoNTA penetrated through muscular layers of the bladder wall and the staining was uniform in the urothelium, interstitium, and muscular layers. Positive IHC staining showed that BoNTA was traced in the upper and lower spinal cord in addition to pelvic nerve, sacral nerve plexus, intestine wall, and pelvic floor muscle. In G2, all the specimens were intact in IHC staining. The presence of BoNTA in lower and upper spinal cord suggests the possibility of retrograde trans-axonal transfer of toxin to lower and upper neural pathways which may result in simultaneous improvement in bladder and bowel functions.
为了检验下述假说,我们采用经膀胱内电动给药(intravesical electromotive drug administration,EMDA)的方式将肉毒毒素 A (botulinum toxin type A,BoNTA)注入膀胱,观察其是否会对改善膀胱功能起到协同作用。我们还试图确认毒素逆行跨神经元转运的可能性。动物研究。将 10 只雄性兔子分为两组。第 1 组(G1)(n=5)接受膀胱内 BoNTA 治疗(BoNTA/EMDA),第 2 组(G2)(n=5)作为对照组。G1 组通过用于 EMDA 的专用导管向膀胱内注射 10IU/Kg 的 BoNTA。毒素用 1ml 蒸馏水稀释,约 0.1-0.15ml。给药装置的最大输送电流为 4mA,持续 15min。在 G2 对照组中,以相同的方式向膀胱内注入生理盐水。术后 1 个月,从膀胱相邻结构采集多处活检样本。使用抗梭菌肉毒毒素 A 型鼠 IgM 单克隆抗体进行免疫组织化学(immunohistochemical,IHC)评估。在 G1 组的标本中,BoNTA 穿透膀胱壁的肌肉层,在尿路上皮、间质和肌肉层中的染色均匀。IHC 染色阳性表明 BoNTA 在上、下脊髓以及盆神经、骶神经丛、肠壁和盆底肌中均有追踪。在 G2 组,所有标本的 IHC 染色均完整。BoNTA 在下、上脊髓中的存在表明毒素可能通过逆行跨神经元转运到下、上神经通路,从而同时改善膀胱和肠道功能。